DesignMedix Management Team: Dr. Lynnor Stevenson, Dr. Sandra Shotwell, David Peyton, Steven Burgess, Jane Kelly

Lynnor Stevenson (Chief Executive Officer) is a successful entrepreneur with thirty years experience in the formation and growth of bioscience companies. Lynnor most recently has been a Managing Partner of Alta Biomedical Group, a consulting firm that handles projects in the commercialization of innovative technology. She has been a member of the early-stage management teams for ten start-up companies, of which six now are public. She was founding CEO for 5 years and a director for 18 years of Heska Corporation, an animal health company that develops drugs, vaccines and diagnostics. She was a member of the early-stage teams for Creative BioMolecules (now Curis), AP Pharma, Agen and Univax (now Nabi). In addition to business and R&D experience relating to drugs, vaccines and diagnostics, she has experience in drug development at several companies including the submission of several IND (Investigational New Drug) applications to the FDA. She received B.Sc.Hon. and B.Ed. degrees from Melbourne University and a Ph.D in Biochemistry from Monash University, Australia.

David Peyton (Chief Scientific Officer) is a Professor of Chemistry at Portland State University, where he has been since 1987. He has carried out research in areas ranging from NMR methods development to biological chemistry, and has been working on infectious disease and malaria drug action for over 15 years. His work on parasites began in 1992 with NMR-based studies of antimalarial drug action. David obtained his BS from Abilene Christian University, his Ph.D from University of California, Santa Barbara and did postdoctoral work at Cornell University Medical College and University of California at Davis.

Team

Call for a quote today! (415) 555-5555

Targeting drug-resistant diseases with dual-action drugs

Sandra Shotwell (Chief Operations Officer) has over 25 years experience in early stage technology commercialization. She has done biotech and pharmaceutical licensing deals for Stanford University, Oregon Health Sciences University, and the National Institutes of Health, where she founded and led the technology licensing program. Sandra most recently has been a Managing Partner of Alta Biomedical Group, a consulting firm that handles

projects in the commercialization of innovative technology. She also is nationally recognized as an authority on the role of intellectual property in the development of neglected diseases. Sandra did her undergraduate work at Princeton University, earned a Ph.D. in Biology from the California Institute of Technology, and did postdoctoral research at Stanford University School of Medicine.

Steven Burgess (Senior Chemist) has over a decade of industry experience in medicinal chemistry. Steven worked at Maybridge Chemical Company for 11 years as a Synthetic Organic Chemist and a Team Leader. Steven obtained his BS from University of Bristol in the U.K., and his Ph.D. from Portland State University, where he worked with David Peyton designing and developing novel antimalarial compounds.

Jane Kelly (Senior Chemist) also is a Research Professor in the Department of Chemistry at Portland State University. She has extensive experience in medicinal and biophysical chemistry, with a strong publication record. Jane obtained her BS from Xiamen University in P.F. China, her MS and PhD from Portland State University, and did her postdoctoral work at the Portalnd VA Medical Center on drug development for malaria and leishmaniasis.